Suboptimal hyperglycemia control,side effects of traditional anti-diabetic agents such as hypoglycemia and weight gain are problems in current treatment for type 2 diabetes.Type 2 diabetes is a complex systemic metabolic disorder,which makes composite outcome measurement a new recommendation in diabetes guidelines.Besides a good glycaemic control,glucagon like peptide-1 analogue liraglutide also has the effects of weight reduction,lowering blood pressure and improvement on β cell function with lower risk of hypoglycemia.Liraglutide Phase Ⅲ clinical trials and meta-analyses confirmed its unique advantages of multiple effects and higher odds of achieving composite outcome,suggesting the potential of liraglutide to improve the overall prognosis of patients with type 2 diabetes.